Reynard Olivier, Nguyen Xuan-Nhi, Alazard-Dany Nathalie, Barateau Véronique, Cimarelli Andrea, Volchkov Viktor E
Molecular Basis of Viral Pathogenicity, CIRI, INSERM, U1111-CNRS UMR5308, Université de Lyon, Université Claude Bernard Lyon 1, Ecole Normale Supérieure de Lyon, Lyon 69007, France.
Host Pathogen interaction during lentiviral infection, CIRI, INSERM, U1111-CNRS UMR5308, Université de Lyon, Université Claude Bernard Lyon 1, Ecole Normale Supérieure de Lyon, Lyon 69007, France.
Viruses. 2015 Dec 1;7(12):6233-40. doi: 10.3390/v7122934.
The current outbreak of Ebola virus (EBOV) in West Africa has claimed the lives of more than 15,000 people and highlights an urgent need for therapeutics capable of preventing virus replication. In this study we screened known nucleoside analogues for their ability to interfere with EBOV replication. Among them, the cytidine analogue β-d-N4-hydroxycytidine (NHC) demonstrated potent inhibitory activities against EBOV replication and spread at non-cytotoxic concentrations. Thus, NHC constitutes an interesting candidate for the development of a suitable drug treatment against EBOV.
目前在西非爆发的埃博拉病毒（EBOV）已导致超过15000人死亡，并凸显出对能够阻止病毒复制的治疗方法的迫切需求。在本研究中，我们筛选了已知的核苷类似物，以评估它们干扰EBOV复制的能力。其中，胞苷类似物β-d-N4-羟基胞苷（NHC）在非细胞毒性浓度下对EBOV的复制和传播表现出强大的抑制活性。因此，NHC是开发针对EBOV的合适药物治疗方法的一个有吸引力的候选物。
